StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX – Get Rating) in a research note issued to investors on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.
Shares of BioLineRx stock opened at $1.66 on Thursday. The business’s 50 day simple moving average is $1.66 and its 200 day simple moving average is $2.23. BioLineRx has a 52-week low of $1.34 and a 52-week high of $6.34. The firm has a market cap of $79.14 million, a PE ratio of -2.27 and a beta of 1.98.
BioLineRx (NASDAQ:BLRX – Get Rating) last announced its earnings results on Wednesday, March 16th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.06. As a group, analysts anticipate that BioLineRx will post -0.56 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new position in shares of BioLineRx during the 4th quarter worth approximately $29,000. Advisor Group Holdings Inc. increased its position in shares of BioLineRx by 105.9% during the 4th quarter. Advisor Group Holdings Inc. now owns 15,253 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 7,844 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of BioLineRx during the 3rd quarter worth approximately $33,000. Millennium Management LLC acquired a new position in shares of BioLineRx during the 2nd quarter worth approximately $42,000. Finally, Geneos Wealth Management Inc. increased its position in shares of BioLineRx by 63.1% during the 4th quarter. Geneos Wealth Management Inc. now owns 28,950 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 11,200 shares during the last quarter. 5.46% of the stock is currently owned by institutional investors and hedge funds.
About BioLineRx
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. Its oncology programs include Motaxafortide (BL-8040), which is therapy platform used in the treatment of pancreatic cancer; and AGI-134 is a immunotherapy treatment used fro multiple solid tumors. The company was founded in April 2003 and is headquartered in Modi’in, Israel.